Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 14Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Neoplasm Metastasis 2Brain Neoplasms 2Uveal Melanoma 1Patient Preference 1Neoplasms 1Melanoma, Cutaneous Malignant 1Lymphoma 1Locally Advanced Melanoma 1Diabetes Mellitus, Insulin-Dependent, 12 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1

Interventions

pembrolizumab 18Nivolumab 13avelumab 10Ipilimumab 7Specimen Handling 6cemiplimab 5atezolizumab 5Magnetic Resonance Spectroscopy 5Biopsy 5Radiotherapy 3Cyclophosphamide 3prednylidene 2poly ICLC 2lutetium Lu 177 dotatate 2fludarabine phosphate 2fludarabine 2durvalumab 2deltacortene 2aldesleukin 2Radiosurgery 2Prednisone 2Interleukin-2 2Immunoglobulin G 2Docetaxel 2CTLA-4 Antigen 2Bevacizumab 2tocilizumab 1talimogene laherparepvec 1sargramostim 1relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Merkel Cell × Opdualag × 1 year × Clear all
NCT06151236 2026-02-17

Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma

Melanoma Institute Australia

Phase 2 Recruiting
20 enrolled
Dermatologic

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡